Table 4.
Clinical Characteristics of Avian Influenza A(H7N9) Case-Patients by Virus Circulation Wave
| Total (N,%) | Wave 1 (n, %) | Wave 2 (n, %) | Wave 3 (n, %) | P | |
|---|---|---|---|---|---|
| Main symptoms at early stage (N1 = 76,N2 = 227,N3 = 169) | |||||
| Fever | 445(94.3) | 74(97.4) | 213(93.8) | 158(93.5) | 0.444 |
| Cough | 386(81.8) | 54(71.1) | 194(85.5) | 138(81.7) | 0.019 |
| Weakness | 186(39.4) | 29(38.2) | 88(38.8) | 69(40.8) | 0.891 |
| Muscle soreness | 107(22.7) | 20(26.3) | 53(23.4) | 34(20.1) | 0.532 |
| Othersa | 170(36) | 37(48.7) | 70(30.8) | 63(37.3) | 0.018 |
| Underlying medical conditions (N1 = 74,N2 = 226,N3 = 166) | 242(51.9) | 43(58.1) | 118(52.2) | 81(48.8) | 0.408 |
| Cardiovascular and cerebrovascular disease | 159(34.1) | 29(39.2) | 69(30.5) | 61(36.8) | 0.266 |
| Metabolic diseases | 68(14.6) | 12(16.2) | 37(16.4) | 19(11.5) | 0.359 |
| Chronic lung disease | 50(10.7) | 12(16.2) | 22(9.7) | 16(9.6) | 0.251 |
| Chronic liver diseases | 32(6.9) | 3(4.1) | 20(8.9) | 9(5.4) | 0.241 |
| Hematological system diseases | 14(3.0) | 1(1.4) | 9(4) | 4(2.4) | 0.441 |
| Cancer | 10(2.1) | 2(2.7) | 6(2.7) | 2(1.2) | 0.580 |
| Rheumatic autoimmune disease | 11(2.4) | 5(6.8) | 2(0.9) | 4(2.4) | 0.015 |
| Immunosuppressive state | 12(2.6) | 1(1.4) | 5(2.2) | 6(3.6) | 0.529 |
| Chronic kidney diseases | 16(3.4) | 1(1.4) | 6(2.7) | 9(5.4) | 0.186 |
| Nervous system or neuromuscular dysfunction | 6(1.3) | 0(0) | 4(1.8) | 2(1.2) | 0.500 |
| Complications (N1 = 71,N2 = 219,N3 = 162) | 406(89.8) | 64(90.1) | 197(90) | 145(89.5) | 0.985 |
| Pneumonia | 392(86.7) | 64(90.1) | 187(85.4) | 141(87.0) | 0.585 |
| Respiratory failure | 311(68.8) | 47(66.2) | 144(65.8) | 120(74.1) | 0.195 |
| Acute Respiratory Distress Syndrome(ARDS) | 298(65.9) | 42(59.2) | 141(64.4) | 115(71) | 0.171 |
| Hepatic insufficiency | 193(42.7) | 25(35.2) | 90(41.1) | 78(48.2) | 0.148 |
| Renal insufficiency | 152(33.6) | 23(32.4) | 68(31.1) | 61(37.7) | 0.391 |
| Septic shock | 141(31.2) | 14(19.7) | 64(29.2) | 63(38.9) | 0.010 |
| Cardiac failure | 124(27.4) | 16(22.5) | 49(22.4) | 59(36.4) | 0.006 |
| Neurologic complications | 27(6.0) | 2(2.8) | 12(5.5) | 13(8.0) | 0.277 |
| Disseminated intravascular coagulation | 25(5.5) | 3(4.2) | 9(4.1) | 13(8.0) | 0.222 |
| Rhabdomyalysis | 17(3.8) | 1(1.4) | 6(2.7) | 10(6.2) | 0.115 |
| Failure of two or more organs | 302(66.8) | 45(63.4) | 139(63.5) | 118(72.8) | 0.127 |
N1: Number of individuals in Wave 1 who had clinical information, N2: Number of individuals in Wave 2 who had clinical information, N3: Number of individuals in Wave 3 who had clinical information
aIncluding shortness of breath, chest distress, expectoration, nausea, vomiting, et al